Avanbulin - Basilea Pharmaceutica
Alternative Names: BAL 27862Latest Information Update: 24 May 2022
At a glance
- Originator Basilea Pharmaceutica
- Class Antineoplastics; Imidazoles; Oxadiazoles; Small molecules
- Mechanism of Action Apoprotein stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 May 2022 Preclinical development in Cancer is ongoing in Switzerland (unspecified route )
- 24 May 2022 Preclinical trials in Cancer in Switzerland (unspecified route)
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Cancer presented at the 113th Annual Meeting of American Association for Cancer Research (AACR-2022)